

CONTENTS

Important Notice	1
Company Profile	2
Change in Share Capital and Shareholdings of Major Shareholders	4
Directors, Supervisors, Senior Management and Staff	6
Management Discussion and Analysis	7
Disclosure of Significant Events	12
Financial Reports:	
<i>Prepared in accordance with Accounting Standards and Systems of the People's Republic of China</i>	15
<i>Prepared in accordance with Statement of Standard Accounting Practice 25 issued by the Hong Kong Society of Accountants</i>	66
Documents Available for Inspection	78

IMPORTANT NOTICE

- 1 The Board of Directors of Guangzhou Pharmaceutical Company Limited (the "Company", and together with its subsidiaries, the "Group") and each director collectively and individually accept full responsibility for the authenticity, accuracy and completeness of the information contained in this interim report and confirm, having made reasonable enquiries, that to the best of their knowledge and belief, that there are no material omissions from or misrepresentations or misleading statements contained in this interim report.
- 2 Mr. Cai Zhixiang, Chairman of the Board, Mr. Zhou Yuejing, Director and General Manager, Mr. Gao Fang, Financial Controller and Mr. Chen Binghua, Senior Finance Manager, individually accept responsibility for ensuring the authenticity and completeness of the financial reports contained in this interim report.
- 3 The financial reports contained in this interim report are unaudited.
- 4 This interim report is prepared in both English and Chinese. In the event that different interpretation occurs, with the exception of the interim financial report prepared in accordance with Statement of Standard Accounting Practice 25, Interim Financial Reporting, issued by the Hong Kong Society of Accountants ("HKSSAP 25"), the Chinese version shall prevail .

The Board of Directors
Guangzhou Pharmaceutical Company Limited